ZA201506530B - Biodegradable and clinically-compatible nanoparticles as drug delivery carriers - Google Patents

Biodegradable and clinically-compatible nanoparticles as drug delivery carriers

Info

Publication number
ZA201506530B
ZA201506530B ZA2015/06530A ZA201506530A ZA201506530B ZA 201506530 B ZA201506530 B ZA 201506530B ZA 2015/06530 A ZA2015/06530 A ZA 2015/06530A ZA 201506530 A ZA201506530 A ZA 201506530A ZA 201506530 B ZA201506530 B ZA 201506530B
Authority
ZA
South Africa
Prior art keywords
biodegradable
clinically
drug delivery
delivery carriers
compatible nanoparticles
Prior art date
Application number
ZA2015/06530A
Other languages
English (en)
Inventor
Dodwadkar Namita
Prata Joseph
Dai Xiaoshu
Saxena Vaibhav
Gada Keyur
Li Youzhi
J Li Chiang
Original Assignee
1Globe Health Inst Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Health Inst Llc filed Critical 1Globe Health Inst Llc
Publication of ZA201506530B publication Critical patent/ZA201506530B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5115Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ceramic Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2015/06530A 2013-02-05 2015-09-04 Biodegradable and clinically-compatible nanoparticles as drug delivery carriers ZA201506530B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361761012P 2013-02-05 2013-02-05
PCT/US2014/014751 WO2014123935A1 (en) 2013-02-05 2014-02-05 Biodegradable and clinically-compatible nanop articles as drug delivery carriers

Publications (1)

Publication Number Publication Date
ZA201506530B true ZA201506530B (en) 2018-11-28

Family

ID=51300093

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/06530A ZA201506530B (en) 2013-02-05 2015-09-04 Biodegradable and clinically-compatible nanoparticles as drug delivery carriers

Country Status (13)

Country Link
US (2) US11001840B2 (cg-RX-API-DMAC7.html)
EP (2) EP2953646B1 (cg-RX-API-DMAC7.html)
JP (1) JP6507102B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150132131A (cg-RX-API-DMAC7.html)
AU (2) AU2014215421A1 (cg-RX-API-DMAC7.html)
CA (1) CA2899155A1 (cg-RX-API-DMAC7.html)
ES (1) ES2873600T3 (cg-RX-API-DMAC7.html)
IL (1) IL240148A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015010083A (cg-RX-API-DMAC7.html)
RU (1) RU2015137815A (cg-RX-API-DMAC7.html)
SG (2) SG10201706968UA (cg-RX-API-DMAC7.html)
WO (1) WO2014123935A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201506530B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150132131A (ko) 2013-02-05 2015-11-25 1글로브 헬스 인스티튜트 엘엘씨 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자
AU2014292926B2 (en) 2013-07-25 2020-03-05 Exicure Operating Company Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US12264344B2 (en) 2014-08-19 2025-04-01 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CA2973702A1 (en) 2015-01-14 2016-07-21 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2017193087A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US10800817B2 (en) * 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
EP3568122B1 (en) * 2017-01-10 2023-10-04 Dukebox SP. Z O.O. A method of manufacturing a suspension of nanoparticles of potassium salt or magnesium salt
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
KR102120482B1 (ko) 2018-10-05 2020-06-08 씨제이제일제당 (주) 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법
US20230149561A1 (en) * 2019-07-12 2023-05-18 The Board Of Trustees Of The Leland Stanford Junior University Functionalized Nanoparticles and Their Use in Treating Bacterial Infections
WO2021067952A1 (en) * 2019-10-04 2021-04-08 The University Of Chicago Targeted nanomedicine for treating vascular disorders
JP2023512688A (ja) * 2020-02-03 2023-03-28 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー 脊髄損傷後の機能回復を促進するためのマイクロrna-7組成物およびその使用方法
US11998615B2 (en) 2021-04-14 2024-06-04 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoparticles and their use in treating bacterial infections

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5879715A (en) * 1997-09-02 1999-03-09 Ceramem Corporation Process and system for production of inorganic nanoparticles
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19912502A1 (de) 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
EP1328254B1 (en) 2000-10-25 2007-02-21 The University Of British Columbia Lipid formulations for target delivery
IN192520B (cg-RX-API-DMAC7.html) * 2001-08-01 2004-04-24 Univ Delhi
JP4951338B2 (ja) 2003-07-16 2012-06-13 プロチバ バイオセラピューティクス インコーポレイティッド 脂質に封入された干渉rna
CN1993113B (zh) 2004-02-13 2010-12-08 Nod药物公司 包含磷酸钙纳米颗粒核心,生物分子和胆汁酸的颗粒,其生产方法,其治疗用途
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
JPWO2007000939A1 (ja) 2005-06-28 2009-01-22 学校法人 聖マリアンナ医科大学 局所炎症治療用薬剤
CN100435784C (zh) * 2005-07-25 2008-11-26 管晓虹 含有和包封中药成分的无机盐纳米粒子的制备方法
US20080248108A1 (en) * 2006-10-06 2008-10-09 Jain Krotz Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions
EP2146691A2 (en) 2007-04-17 2010-01-27 Baxter International Inc. Nucleic acid microparticles for pulmonary delivery
CA2694089A1 (en) * 2007-07-16 2009-01-22 Northeastern University Therapeutic stable nanoparticles
DK2193140T3 (en) * 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
EP2197454A4 (en) 2007-09-25 2012-07-04 Idexx Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
CN101945654B (zh) 2007-12-14 2012-06-27 江崎格力高株式会社 α-硫辛酸纳米颗粒及其制备方法
CA2710983A1 (en) 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
US9006193B2 (en) 2008-05-13 2015-04-14 University Of Washington Polymeric carrier
WO2010062941A1 (en) 2008-11-26 2010-06-03 University Of Kansas Nucleic acid delivery compositions and methods
ATE544472T1 (de) * 2008-12-19 2012-02-15 Biolitec Ag Kalziumphosphat-nanopartikel als farbstoffträger für die photodynamische therapie
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
US20120220647A1 (en) * 2009-09-14 2012-08-30 Jin-Ho Choy Nano-hybrid of targetable sirna-layered inorganic hydroxide, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising the nano-hybrid
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
US20130236396A1 (en) * 2010-05-03 2013-09-12 University Of Utah Research Foundation Nanoparticles produced from recombinant polymers and methods of making and using the same
US9375400B2 (en) * 2011-09-14 2016-06-28 University Of South Florida Manganese ion coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation
SI2773326T1 (sl) 2011-11-04 2019-04-30 Nitto Denko Corporation Metoda za sterilno proizvodnjo delcev lipidno-nukleinske kisline
US20130243699A1 (en) * 2011-12-07 2013-09-19 Regents Of The University Of Minnesota Biodegradable Magnetic Nanoparticles and Related Methods
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
KR20150132131A (ko) 2013-02-05 2015-11-25 1글로브 헬스 인스티튜트 엘엘씨 약물 전달 담체로서 생체분해가능하고 임상적으로 상용가능한 나노입자

Also Published As

Publication number Publication date
JP2016513090A (ja) 2016-05-12
AU2018200903A1 (en) 2018-02-22
WO2014123935A1 (en) 2014-08-14
KR20150132131A (ko) 2015-11-25
SG10201706968UA (en) 2017-09-28
RU2015137815A (ru) 2017-03-13
SG11201506116XA (en) 2015-09-29
HK1217906A1 (en) 2017-01-27
WO2014123935A9 (en) 2014-10-23
US20210230595A1 (en) 2021-07-29
EP2953646B1 (en) 2021-03-10
CA2899155A1 (en) 2014-08-14
US20160046936A1 (en) 2016-02-18
EP2953646A4 (en) 2017-02-15
EP2953646A1 (en) 2015-12-16
US11001840B2 (en) 2021-05-11
ES2873600T3 (es) 2021-11-03
MX2015010083A (es) 2016-04-26
AU2014215421A1 (en) 2015-08-13
IL240148A0 (en) 2015-09-24
EP3845248A1 (en) 2021-07-07
JP6507102B2 (ja) 2019-04-24

Similar Documents

Publication Publication Date Title
ZA201506530B (en) Biodegradable and clinically-compatible nanoparticles as drug delivery carriers
SG11201500937UA (en) Extrusion methods and devices for drug delivery
IL240849A0 (en) Drug delivery devices and drug delivery method
PL2968880T3 (pl) Urządzenia do dostarczania leku ze składnikiem przepuszczalnym dla leku
ZA201505735B (en) Cancer drug and uses
GB201313782D0 (en) Drug delivery device
IL245544A0 (en) drug delivery system
ZA201500299B (en) Drug delivery device
IL236745A0 (en) Drug release device
SI3081249T1 (sl) Naprava za dajanje zdravila
GB201302427D0 (en) Nanoparticle delivery compositions
SG11201600371XA (en) Drug delivery device
GB201314312D0 (en) Composition and delivery system
EP2903659A4 (en) INTRAVENOUS MEDICAMENT DELIVERY SYSTEM
IL234912A0 (en) Drug release device
IL245007A0 (en) Drug release device
GB201319437D0 (en) Delivery of drugs
EP3079664A4 (en) Regionally activated drug delivery nanoparticles
GB201404358D0 (en) Improvements in drug delivery inhalar devices
EP3043721A4 (en) PHARMACOLOGICAL DELIVERY SYSTEMS AND ASSOCIATED METHODS
AU2013901119A0 (en) Nanoparticles for drug delivery
GB201303577D0 (en) Drug delivery device
GB201301385D0 (en) Particle structures for drug delivery
HUE049546T2 (hu) Gyógyszerbejuttató eszköz
HUE049542T2 (hu) Gyógyszerbejuttató eszköz